About tonix pharmaceuticals - TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
TNXP At a Glance
Tonix Pharmaceuticals Holding Corp.
26 Main Street
Chatham, New Jersey 07928
| Phone | 1-862-799-8599 | Revenue | 7.77M | |
| Industry | Pharmaceuticals: Major | Net Income | -116,658,000.00 | |
| Sector | Health Technology | Employees | 103 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
TNXP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.884 |
| Price to Book Ratio | 0.224 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.072 |
| Enterprise Value to Sales | -1.064 |
| Total Debt to Enterprise Value | -1.187 |
TNXP Efficiency
| Revenue/Employee | 75,417.476 |
| Income Per Employee | -1,132,601.942 |
| Receivables Turnover | 1.692 |
| Total Asset Turnover | 0.041 |
TNXP Liquidity
| Current Ratio | 2.53 |
| Quick Ratio | 1.78 |
| Cash Ratio | 1.321 |
TNXP Profitability
| Gross Margin | -16.272 |
| Operating Margin | -1,523.944 |
| Pretax Margin | -1,501.777 |
| Net Margin | -1,501.777 |
| Return on Assets | -61.375 |
| Return on Equity | -74.612 |
| Return on Total Capital | -101.144 |
| Return on Invested Capital | -72.859 |
TNXP Capital Structure
| Total Debt to Total Equity | 9.299 |
| Total Debt to Total Capital | 8.508 |
| Total Debt to Total Assets | 6.353 |
| Long-Term Debt to Equity | 6.816 |
| Long-Term Debt to Total Capital | 6.236 |